- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03312465
Anatomical Shoulder Domelock System Study
Anatomical Shoulder™ Domelock System A Multicenter, Prospective and Retrospective, Non-Controlled Post-Market Clinical Follow-up Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- Universitaire Ziekenhuizen Leuven
-
-
-
-
-
Daun, Germany
- Krankenhaus Maria Hilf
-
Hamburg, Germany
- HELIOS ENDO-Klinik Hamburg
-
-
-
-
-
Basel, Switzerland
- Universitätsspital Basel
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Switzerland, 8008
- Univeritätklinik Bagrist
-
-
-
-
-
Derby, United Kingdom, DE22 3NE
- Royal Derby Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is 18-80 years of age, inclusive
- Patient is skeletally mature
- Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history
- Patient has failed conservative treatment
Patient meets at least one of the following indications:
- Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis if bone stock is adequate.
- Avascular necrosis
- Conditions consequent to earlier operations
- Optional use in revision: in some medical conditions (e.g., early revision when adequate bone stock exists), the surgeon may opt to use primary implants in a revision procedure.
Additional criteria for retrospective patients:
- patient has been implanted with the Domelock system before site initiation visit.
- information available must include at minimum demographic information, the operative report and details of the device implanted.
Exclusion Criteria:
- Patient is unwilling or unable to give consent or to comply with the follow-up program
- Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them
- Patient is known to be pregnant or breastfeeding
Patient meets at least one of the contraindications:
- Patient's physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant, e.g., previous surgery, insufficient quality or quantity of bone, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention e.g., absence of musculoligamentous supporting structures, joint neuropathy or other conditions that may lead to inadequate skeletal fixation
- Signs of infection
- Severe instability secondary to advanced loss of osteochondral structure
- Charcot's shoulder (neuroarthropathy)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
AS Domelock System Subjects
Subjects that receive the Anatomical Shoulder Domelock System
|
Hemi or Total Shoulder Arthroplasty
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Survivorship
Time Frame: 10 Years
|
The primary endpoint of this study is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method.
|
10 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Performance
Time Frame: 5 Years
|
The secondary endpoint is defined by the performance of the Anatomical Shoulder Domelock System at 5 years, which is assessed by the Constant and Murley score. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points. |
5 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Emilie Rohmer, Zimmer Biomet Clinical Operations
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Pathologic Processes
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Necrosis
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Osteoarthritis
- Arthritis, Rheumatoid
- Osteonecrosis
Other Study ID Numbers
- CME2014-07E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Richard Burt, MDTerminated
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on AS Domelock System
-
Renmin Hospital of Wuhan UniversityShanghai Pudong Hospital; The Eighth Hospital of Wuhan; Jinjiang Municipal Hospital...RecruitingArtificial Intelligence | SurveillanceChina
-
Renmin Hospital of Wuhan UniversityNot yet recruitingArtificial Intelligence | SurveillanceChina
-
Dr Willem BassonSunshine Coast Hospital and Health ServiceWithdrawn
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance AbuseUnited States
-
Renmin Hospital of Wuhan UniversityJiangmen Central HospitalNot yet recruitingArtificial Intelligence | SurveillanceChina
-
Marc Bosiers, MDBentley InnoMed GmbHActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingAccuracy of Dynamic Navigation System in Implant Placement for Full Arch Prosthesis RehabilitationVietnam
-
Chang Gung Memorial HospitalCompletedAnesthesia, General | Intubation, Intratracheal | LaryngoscopesTaiwan
-
Penumbra Inc.CompletedAssessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities (SURF)Aneurysm, BrainUnited States, Germany, Switzerland, Spain, Canada, Italy
-
Zimmer BiometWithdrawnOsteoarthritis | Degenerative Arthritis